Recon Strategy
Contact

Insights

Fifteen+ years of
Healthcare thinking.

Several hundred perspectives on the questions facing payers, providers, biopharma, medtech, and digital health — plus our running read on the clinical literature. Start with our sharpest work, or filter to your world.

Sector
All
NEJM opinion

Outcomes Based Arrangements in Biopharma

  • Biopharma , 
  • Payers , 
  • Institutional
Today’s advanced therapies target devastating diseases with high unmet need. Given the urgent medical need (and pressure from patient advocates), regulators increasingly must make decisions based on early, incomplete data when it comes to durability, real-world effectiveness, and cost-effectiveness – all while bearing costs that can exceed $1 million per patient.

Read more

An innovative sales strategy for a pivotal drug; Novartis trailblazes with Leqvio

  • Biopharma
After the $9.7B acquisition of The Medicines Company two and a half ye…

Read more

NEJM Highlights May 2015: a read on ACO performance, progress in cystic fibrosis treatment, yes developing new drugs is expensive, rethinking industry-medicine relationships, CVS Caremark and smoking cessation

  • NEJM
Early results of the ACO experiment: directionally right, but impact i…

Read more

Biopharma innovation: Will there be sufficient incentives in the future?

  • Biopharma
Ezekiel Emanuel wrote an op-ed in the New York Times last month, which…

Read more